{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:27:21Z","timestamp":1778113641480,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,10]]},"DOI":"10.7759\/cureus.91949","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T07:07:47Z","timestamp":1757488067000},"source":"Crossref","is-referenced-by-count":1,"title":["Fenfluramine and Comparative Antiseizure Therapies in Drug-Resistant Epilepsy: A Systematic Review of Efficacy, Cardiometabolic Safety, and Clinical Outcomes"],"prefix":"10.7759","author":[{"given":"Ashis","family":"Pal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavna","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivam","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Habib Ur Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momina","family":"Abid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aqib","family":"Imran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fepid.2023.1273163","article-title":"Editorial: epidemiology of epilepsy and seizures","volume":"3","author":"Chen Z","year":"2023","unstructured":"Chen Z, Brodie MJ, Ding D, Kwan P. Editorial: epidemiology of epilepsy and seizures. Front Epidemiol. 2023, 3:1273163. 10.3389\/fepid.2023.1273163","journal-title":"Front Epidemiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.120.019539","article-title":"Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options","volume":"72","author":"L\u00f6scher W","year":"2020","unstructured":"L\u00f6scher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020, 72:606-38. 10.1124\/pr.120.019539","journal-title":"Pharmacol Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13091305","article-title":"A comprehensive review of emerging trends and innovative therapies in epilepsy management","volume":"13","author":"Ghosh S","year":"2023","unstructured":"Ghosh S, Sinha JK, Ghosh S, Sharma H, Bhaskar R, Narayanan KB. A comprehensive review of emerging trends and innovative therapies in epilepsy management. Brain Sci. 2023, 13:1305. 10.3390\/brainsci13091305","journal-title":"Brain Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00827-8","article-title":"The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond","volume":"35","author":"L\u00f6scher W","year":"2021","unstructured":"L\u00f6scher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021, 35:935-63. 10.1007\/s40263-021-00827-8","journal-title":"CNS Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-010-0080-y","article-title":"Antiepileptic drugs and markers of vascular risk","volume":"12","author":"Lopinto-Khoury C","year":"2010","unstructured":"Lopinto-Khoury C, Mintzer S. Antiepileptic drugs and markers of vascular risk. Curr Treat Options Neurol. 2010, 12:300-8. 10.1007\/s11940-010-0080-y","journal-title":"Curr Treat Options Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1156952","article-title":"Association of epilepsy, anti-epileptic drugs (AEDs), and type 2 diabetes mellitus (T2DM): a population-based cohort retrospective study, impact of AEDs on T2DM-related molecular pathway, and via peroxisome proliferator-activated receptor \u03b3 transactivation","volume":"14","author":"Tien N","year":"2023","unstructured":"Tien N, Wu TY, Lin CL, et al.. Association of epilepsy, anti-epileptic drugs (AEDs), and type 2 diabetes mellitus (T2DM): a population-based cohort retrospective study, impact of AEDs on T2DM-related molecular pathway, and via peroxisome proliferator-activated receptor \u03b3 transactivation. Front Endocrinol (Lausanne). 2023, 14:1156952. 10.3389\/fendo.2023.1156952","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2020.16.4.556","article-title":"Pharmacological treatment of epilepsy in elderly patients","volume":"16","author":"Seo JG","year":"2020","unstructured":"Seo JG, Cho YW, Kim KT, et al.. Pharmacological treatment of epilepsy in elderly patients. J Clin Neurol. 2020, 16:556-61. 10.3988\/jcn.2020.16.4.556","journal-title":"J Clin Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211037430","article-title":"Efficacy and tolerability of antiseizure drugs","volume":"14","author":"Hakami T","year":"2021","unstructured":"Hakami T. Efficacy and tolerability of antiseizure drugs. Ther Adv Neurol Disord. 2021, 14:17562864211037430. 10.1177\/17562864211037430","journal-title":"Ther Adv Neurol Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021, 10:89. 10.1186\/s13643-021-01626-4","journal-title":"Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0829","article-title":"Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial","volume":"79","author":"Knupp KG","year":"2022","unstructured":"Knupp KG, Scheffer IE, Ceulemans B, et al.. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022, 79:554-64. 10.1001\/jamaneurol.2022.0829","journal-title":"JAMA Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18342","article-title":"Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome","volume":"66","author":"Scheffer IE","year":"2025","unstructured":"Scheffer IE, Nabbout R, Lagae L, et al.. Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. Epilepsia. 2025, 66:1919-32. 10.1111\/epi.18342","journal-title":"Epilepsia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17431","article-title":"Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study","volume":"64","author":"Knupp KG","year":"2023","unstructured":"Knupp KG, Scheffer IE, Ceulemans B, et al.. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2023, 64:139-51. 10.1111\/epi.17431","journal-title":"Epilepsia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2022-0197","article-title":"Standard and high dose ergocalciferol regimens for treatment of hypovitaminosis D in epileptic children and adolescents","volume":"35","author":"Vichutavate S","year":"2022","unstructured":"Vichutavate S, Suwanpakdee P, Likasitthananon N, Numbenjapon N, Nabangchang C, Phatarakijnirund V. Standard and high dose ergocalciferol regimens for treatment of hypovitaminosis D in epileptic children and adolescents. J Pediatr Endocrinol Metab. 2022, 35:1369-76. 10.1515\/jpem-2022-0197","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109939","article-title":"Efficacy of oral sodium chloride in reducing the incidence of hyponatremia in children with epilepsy receiving oxcarbazepine monotherapy: a randomized controlled trial (SCHO trial)","volume":"158","author":"Neha KC","year":"2024","unstructured":"Neha KC, Panda PK, Mirza AA, Dhamija P, Sharawat IK. Efficacy of oral sodium chloride in reducing the incidence of hyponatremia in children with epilepsy receiving oxcarbazepine monotherapy: a randomized controlled trial (SCHO trial). Epilepsy Behav. 2024, 158:109939. 10.1016\/j.yebeh.2024.109939","journal-title":"Epilepsy Behav"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107148","article-title":"Evaluation of factors influencing obesity and the effect of a 12-week home-based exercise program in people with epilepsy - randomized control trial","volume":"110","author":"SudhindraVooturi","year":"2020","unstructured":"SudhindraVooturi, Lakshmi AN, Jayalakshmi S. Evaluation of factors influencing obesity and the effect of a 12-week home-based exercise program in people with epilepsy - randomized control trial. Epilepsy Behav. 2020, 110:107148. 10.1016\/j.yebeh.2020.107148","journal-title":"Epilepsy Behav"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01097-5","article-title":"Safety of eslicarbazepine acetate in elderly versus non-elderly patients with focal seizures: from pooled data of clinical studies to 8 years of post-marketing experience","volume":"44","author":"Magalh\u00e3es LM","year":"2021","unstructured":"Magalh\u00e3es LM, Costa R, Vieira M, Moreira J, Gama H, Soares-da-Silva P. Safety of eslicarbazepine acetate in elderly versus non-elderly patients with focal seizures: from pooled data of clinical studies to 8 years of post-marketing experience. Drug Saf. 2021, 44:1099-107. 10.1007\/s40264-021-01097-5","journal-title":"Drug Saf"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106989","article-title":"Fenfluramine acts as a positive modulator of sigma-1 receptors","volume":"105","author":"Martin P","year":"2020","unstructured":"Martin P, de Witte PA, Maurice T, Gammaitoni A, Farfel G, Galer B. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020, 105:106989. 10.1016\/j.yebeh.2020.106989","journal-title":"Epilepsy Behav"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16638","article-title":"Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study","volume":"61","author":"Lai WW","year":"2020","unstructured":"Lai WW, Galer BS, Wong PC, Farfel G, Pringsheim M, Keane MG, Agarwal A. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study. Epilepsia. 2020, 61:2386-95. 10.1111\/epi.16638","journal-title":"Epilepsia"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001769.pub3","article-title":"Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review","volume":"4","author":"Nolan SJ","year":"2016","unstructured":"Nolan SJ, Marson AG, Weston J, Tudur Smith C. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review. Cochrane Database Syst Rev. 2016, 4:CD001769. 10.1002\/14651858.CD001769.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-019-0957-4","article-title":"Incidence, implications, and management of seizures following ischemic and hemorrhagic stroke","volume":"19","author":"Doria JW","year":"2019","unstructured":"Doria JW, Forgacs PB. Incidence, implications, and management of seizures following ischemic and hemorrhagic stroke. Curr Neurol Neurosci Rep. 2019, 19:37. 10.1007\/s11910-019-0957-4","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ph15040475","article-title":"Levetiracetam mechanisms of action: from molecules to systems","volume":"15","author":"Contreras-Garc\u00eda IJ","year":"2022","unstructured":"Contreras-Garc\u00eda IJ, C\u00e1rdenas-Rodr\u00edguez N, Romo-Mancillas A, et al.. Levetiracetam mechanisms of action: from molecules to systems. Pharmaceuticals (Basel). 2022, 15:475. 10.3390\/ph15040475","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.743138","article-title":"Impact of polypharmacy, drug-related problems, and potentially inappropriate medications in geriatric patients and its implications for Bulgaria - narrative review and meta-analysis","volume":"10","author":"Krustev T","year":"2022","unstructured":"Krustev T, Milushewa P, Tachkov K. Impact of polypharmacy, drug-related problems, and potentially inappropriate medications in geriatric patients and its implications for Bulgaria - narrative review and meta-analysis. Front Public Health. 2022, 10:743138. 10.3389\/fpubh.2022.743138","journal-title":"Front Public Health"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.17712\/nsj.2022.2.20210144","article-title":"Early seizures in stroke - frequency, risk factors, and effect on patient outcomes in a tertiary center in Saudi Arabia","volume":"27","author":"Alsaad F","year":"2022","unstructured":"Alsaad F, Alkeneetir N, Almatroudi M, Alatawi A, Alotaibi A, Aldibasi O, Khatri IA. Early seizures in stroke - frequency, risk factors, and effect on patient outcomes in a tertiary center in Saudi Arabia. Neurosciences (Riyadh). 2022, 27:104-10. 10.17712\/nsj.2022.2.20210144","journal-title":"Neurosciences (Riyadh)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2330","article-title":"Antiseizure medications for post-stroke epilepsy: a real-world prospective cohort study","volume":"11","author":"Tanaka T","year":"2021","unstructured":"Tanaka T, Fukuma K, Abe S, et al.. Antiseizure medications for post-stroke epilepsy: a real-world prospective cohort study. Brain Behav. 2021, 11:e2330. 10.1002\/brb3.2330","journal-title":"Brain Behav"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/402630-fenfluramine-and-comparative-antiseizure-therapies-in-drug-resistant-epilepsy-a-systematic-review-of-efficacy-cardiometabolic-safety-and-clinical-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T07:07:48Z","timestamp":1757488068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/402630-fenfluramine-and-comparative-antiseizure-therapies-in-drug-resistant-epilepsy-a-systematic-review-of-efficacy-cardiometabolic-safety-and-clinical-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.91949","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}